MyBioGate is organizing one of the industry’s leading events in Hamburg, Germany and participants can avail of an early bird discount.
HOUSTON (PRWEB) OCTOBER 04, 2019
Representatives with MyBioGate (https://events.mybiogate.com/) announced that China [email protected] 2019 will be held November 10 at the Grand Elysée Hamburg Rothenbaumchaussee in Hamburg.
“To better connect Chinese companies and European markets, China Focus comes to Europe again this November,” said Miao Guo, Vice President of Operations and spokesperson for MyBioGate.
Guo went on to highlight that China [email protected] will bring together investors, pharma leaders, and innovators from China and around the world for an exclusive partnering event designed to inspire, educate and foster cross-border investment and collaboration in leading biopharma innovations.
Guo noted that the event would feature keynote speech, panel discussions, Chinese companies showcase, 1-on-1 meetings, and company presentations (Pitch & Match).
Guo added that Forum Admissions are available at an early bird rate of €845+19% VAT after a discount of €150, and Group discounts are available for 3 or more attendees. Company presentations (Pitch & Match) also has a €500 off for the first 5 registrants. Send inquiry to info (at) mybiogate (dot) com for more details.
“The pharma market in China grew to about Rmb1,558bn (US$226bn) in 2018, at a CAGR of 10% in 2013-18, becoming the 2nd largest pharma market in the world,” Guo highlighted, before adding, “as the youngest member of ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use), China joined with the least experience but holding the promise to bring domestic clinical trials to world standard and open its market. There will be new revenues for innovative therapeutics and more business development opportunities for global players. The current U.S.-China relationship and CFIUS regulations in the U.S. derived interest from some Chinese investors to the European market.”
Regarding the topics to be discussed at the event, Guo explained that the topics include: NMPA (previously CFDA) regulatory reforms and new opportunities for biotech & pharma; opportunities and barriers for new Chinese players entering the market; new IPO opportunities and the impact on the valuation of biotech companies; European biotech space: how is it unique?; and current and future hot spots in modality and therapeutic area – how can China and Europe join forces?
China [email protected] 2019, according to Guo, is designed to provide a meaningful platform to inform, inspire, and foster cross-border partnerships in life science and healthcare.
The event will feature speakers such as Stephen Sunderland, Partner, L.E.K. Consulting; Dong Chen, Senior Director and China head of business development, Jiangsu Hengrui Medicine; Sebastian Gensior, Founder, Sino-European Pharma Forum (SEPF); Managing Director, Global Health Access Solutions; James Huang, Managing Partner, KPCB China, and more to be announced soon.
For more information, please visit: https://events.mybiogate.com/europe/.
About China Focus
China Focus brings together investors, pharma leaders, and innovators from China and around the world for an exclusive partnering event designed to inspire, educate, and foster cross-border investment and collaboration in leading biopharma innovations.
7707 Fannin Street
Houston, TX 77054
Phone: (832) 497-2220
Email: feier.chen at mybiogate.com
Source: MyBioGate Inc. (event.mybiogate.com)